Open, randomized, multicenter phase II trial with cetuximab /5-FU/FA/irinotecan or cetuximab/5-FU/FA /irinotecan/oxaliplatin in k-ras/b-raf wild type patients or with irinotecan/oxaliplatin/5-FU/FA with or without bevacizumab in k-ras mutant patients as neoadjuvant treatment in patients with non- resectable colorectal liver metastases

Trial Profile

Open, randomized, multicenter phase II trial with cetuximab /5-FU/FA/irinotecan or cetuximab/5-FU/FA /irinotecan/oxaliplatin in k-ras/b-raf wild type patients or with irinotecan/oxaliplatin/5-FU/FA with or without bevacizumab in k-ras mutant patients as neoadjuvant treatment in patients with non- resectable colorectal liver metastases

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Sep 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer; Liver metastases
  • Focus Therapeutic Use
  • Acronyms CELIM2
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Feb 2013 Planned End Date changed from 4 Dec 2016 to 1 Jul 2020 as reported by ClinicalTrials.gov. record.
    • 28 Feb 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health: NCT01802645).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top